Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | GD2Bi-aATC |
Trade Name | |
Synonyms | anti-CD3 x hu3F8 bispecific antibody-armed ATC |
Drug Descriptions |
GD2Bi-aATC are autologous T-cells that have been armed with bispecific antibodies that target both GD2 and CD3, resulting in cytotoxicity of GD2-expressing tumor cells by cross-linking activated T-cells to GD2-positive tumor cells, and may also enhance CTL-mediated response tumor cells (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C116330 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Aldesleukin + GD2Bi-aATC + Sargramostim | Aldesleukin GD2Bi-aATC Sargramostim | 0 | 1 |
GD2Bi-aATC | GD2Bi-aATC | 0 | 0 |